Welcome to our dedicated page for Oncotelic Therapeutics news (Ticker: OTLC), a resource for investors and traders seeking the latest updates and insights on Oncotelic Therapeutics stock.
Oncotelic Therapeutics, Inc. reports developments as a clinical-stage biopharmaceutical company focused on oncology, immunotherapy and rare-disease therapeutics. Company updates cover its internal drug pipeline, orphan oncology programs, antisense and small molecule injectable drug candidates, and partnerships or joint ventures used to license and co-develop selected candidates.
Recurring OTLC news also includes the PDAOAI AI platform for research, biomarker discovery, regulatory processes and GMP-compliant robotics, the company's 45% interest in GMP Bio and related Sapu Bio and Sapu Nano programs, and completed portfolio actions such as field-specific monetization of N2B nose-to-brain delivery assets.
Oncotelic (OTLC)-owned JV Sapu Nano announced a Deciparticle-led biomarker framework that identifies tumors likely to respond to IV Sapu003, an intravenous everolimus nanomedicine. The analysis evaluated >9,000 patient tumor samples across 20 cancer types and found a High-RICTOR / Low-RPTOR gene-expression signature linked to greater mTOR dependency and predicted sensitivity to IV Sapu003. The signature is enriched in HR+/HER2- breast cancer, lung adenocarcinoma, gastric, renal cell, ovarian, AML and T-cell malignancies. Sapu003 is reported to reduce GI accumulation by 67×, increase tumor tissue penetration, and enable biomarker-driven patient selection. Data will be presented at the 2025 San Antonio Breast Cancer Symposium (Dec 9-12, 2025).
Oncotelic (OTLC) and Sapu Nano reported new preclinical pharmacokinetic and tissue distribution data for Sapu003 (IV everolimus) on Dec 3, 2025. The data show IV Sapu003 markedly reduces gastrointestinal drug accumulation versus oral everolimus: stomach exposure down 67-fold, small intestine down 15.7-fold, and large intestine down 7.4-fold. IV dosing produced GI tissue:plasma ratios of 36–48× versus much higher ratios after oral dosing (stomach 2,448×, small intestine 750×, large intestine 323×). The release notes potential for improved tolerability, more consistent systemic exposure, and previously reported 97–98% tumor inhibition in a xenograft model, supporting a Phase I rationale in HR+/HER2- metastatic breast cancer.
Oncotelic (OTLC)-owned joint venture Sapu Nano announced Dec 2, 2025 that its proprietary Deciparticle™ platform reproducibly formulates structurally diverse hydrophobic therapeutics into precise sub-20 nm nanoparticles suitable for IV delivery.
Key findings presented at SABCS 2025: monodisperse ~15 nm Deciparticles encapsulate five macrolide mTOR inhibitors (sirolimus, temsirolimus, ridaforolimus, umirolimus, everolimus), ascomycin macrolactam tacrolimus, and peptide drugs (cyclosporine A, exenatide). Pimecrolimus produced particles above the sub-20 nm threshold, defining a steric limit.
Sapu Nano reported an ISO-5 cGMP manufacturing suite supporting one-pot bulk drug manufacturing, sterile filtration, automated fill/finish, lyophilization, tight lot-to-lot particle-size control, and the ability to support multiple INDs annually.
Oncotelic Therapeutics (OTCQB: OTLC) announced a pending major fair-value update for its 45% ownership in JV partner GMP Bio after a new independent valuation indicated a substantial increase in the asset’s worth. The company was featured in an editorial about rising biotech valuations as clinical platforms advance toward commercialization.
The release frames GAAP fair-value adjustments as investor signals that translate research progress into measurable economic impact and says the JV revaluation reinforces Oncotelic’s position in the oncology-treatment space.
Oncotelic Therapeutics (OTCQB: OTLC) on Nov 21, 2025 highlighted placement in an editorial by BioMedWire and disclosed a forthcoming GAAP fair-value remeasurement of its 45% stake in JV entity GMP Bio after a new independent valuation indicated a potential step-up in asset value.
The announcement frames fair-value remeasurements as a bridge between late-stage biotech progress and shareholder value and says the independent valuation could strengthen Oncotelic's position in oncology as the company advances the JV asset review.
Oncotelic Therapeutics (OTLC) announced a third-party preliminary valuation by Frost & Sullivan valuing the GMP Bio joint venture pipeline at approximately $1.7 billion on Nov 20, 2025. Oncotelic's 45% ownership implies an illustrative potential value of about $765 million to Oncotelic.
The valuation is non-binding and forward-looking; Oncotelic has begun an ASC-compliant valuation for U.S. GAAP reporting and said any material increase would be recorded per fair-value rules. The JV has advanced OT-101 into Phase 3 PDAC, supports multiple clinical candidates on the Deciparticle™ platform, operates a GMP-licensed San Diego facility, and is preparing for a potential Hong Kong IPO in late 2026.
Oncotelic Therapeutics (OTLC) and JV partner Sapu Bioscience published a review titled “Sub-15 nm Nanoparticles for Drug Delivery” in International Journal of Molecular Sciences on Nov 11, 2025.
The paper systematically examines nanoparticles sized 5–15 nm and highlights distinct advantages: deeper tumor penetration, reduced reticuloendothelial accumulation with rapid renal clearance, enhanced barrier diffusion including the blood–brain barrier, and quantum-scale surface properties enabling multifunctional imaging and therapy. The review links findings to Sapu’s Deciparticle™ platform and Sapu-003, an intravenous everolimus nanomedicine preparing for first-in-human evaluation.
Oncotelic Therapeutics (OTCQB: OTLC) was featured in an editorial published Oct 30, 2025 highlighting advances in nanomedicine for oncology drug delivery.
The piece frames industry trends toward precision drug‑delivery systems that aim to improve bioavailability, tumor targeting and therapeutic index while limiting toxicity. It notes growing regulator interest in nanocarrier technologies and positions Oncotelic's proprietary Deciparticle™ platform as a technology intended to enhance the bioavailability and therapeutic index of existing cancer drugs and to improve performance of underutilized compounds.
Oncotelic Therapeutics (OTLC) announced that Sapu Nano's investigational intravenous Deciparticle™ everolimus (Sapu003) has been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS), December 9–12, 2025, in San Antonio, TX. The company said the accepted abstracts cover clinical rationale, molecular biomarkers, and pharmacokinetic support for an ongoing Phase 1 trial of Sapu003 in HR+/HER2- metastatic breast cancer, renal cell carcinoma (RCC), and neuroendocrine tumors (NET).
The presentation session is scheduled for Thursday, December 11, 2025, 5:00 PM–6:30 PM CST and includes three abstracts focused on a RICTOR/RPTOR biomarker signature, formulation and manufacturing, and pharmacokinetic rationale for IV everolimus.
Oncotelic Therapeutics (OTCQB: OTLC) on Oct 28, 2025 highlighted nanomedicine editorial placement and clinical progress for its Deciparticle(TM) drug‑delivery platform.
The company noted placement in a NetworkNewsWire editorial and said its intravenous Deciparticle formulation of everolimus, Sapu‑003, has advanced into human trials, positioning the platform to potentially increase bioavailability and therapeutic index of underperforming oncology drugs.